Among these lesions, the most common are inactivating mutations and/or deletions of the genes encoding the KMT2D histone lysine methyltransferase and the CREBBP acetyltransferase, accounting for 80 to 60% of FL cases and 60 to 40% of DLBCL cases belonging to the recently identified EZB/C3 genetic cluster (5, , , , –10). Here, KMT2D is linked to diffuse large B-cell lymphoma.